Pomalidomide

Small molecule

Also known as CC-4047

Approvedregulatory verdict

Evidence outlook

Approved: Multiple Myeloma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
US
  • Kaposi Sarcoma POMALYST is indicated for the treatment of: • Adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART). • Kaposi sarcoma (KS) in adult patients who are HIV-negative. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Product first approved 2013Outside this platform's coverageFDA label
EU
  • Imnovid: multiple myeloma, with bortezomib and dexamethasone after at least one lenalidomide-containing treatment, or with dexamethasone after at least two prior therapies
Product first approved 2013EMA
JP
  • Pomalyst Capsules (Celgene K.K.): relapsed or refractory multiple myeloma
PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (30)
Multiple Myeloma
NCT07222761 · Regeneron Pharmaceuticals
2026-01-02 – 2034-08-23 · Relapsed and/or Refractory Multiple Myeloma (RRMM)
What this study did
NCT07555938 · Hoffmann-La Roche
2026-06-23 – 2033-01-31 · Multiple Myeloma
What this study did
NCT06615479 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2025-03-12 – 2032-06-22 · Relapsed or Refractory Multiple Myeloma (RRMM)
What this study did
NCT07772024 · CellCentric Ltd.
2026-08 – 2031-11 · Multiple Myeloma Refractory, Multiple Myeloma in Relapse
What this study did
NCT05572515 · Janssen Research & Development, LLC
2023-03-29 – 2031-08-31 · Multiple Myeloma
What this study did
NCT04484623 · GlaxoSmithKline
2020-10-01 – 2029-06-25 · Multiple Myeloma
What this study did
NCT06956170 · GlaxoSmithKline
2022-02-10 – 2029-06-25 · Multiple Myeloma
What this study did
NCT05028348 · European Myeloma Network B.V.
2022-04-19 – 2029-03 · Multiple Myeloma
What this study did
A Study of Daratumumabactive not recruiting
NCT05438043 · Janssen Research & Development, LLC
2022-12-15 – 2029-01-31 · Multiple Myeloma
What this study did
NCT06742138 · Qilu Pharmaceutical Co., Ltd.
2025-01 – 2028-12 · Multiple Myeloma
What this study did
NCT06508983 · Hangzhou Sumgen Biotech Co., Ltd.
2024-06-14 – 2028-03-31 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT05405166 · Sanofi
2022-06-23 – 2027-10-22 · Plasma Cell Myeloma Recurrent
What this study did
NCT03651128 · Celgene
2019-04-16 – 2026-04-13 · Multiple Myeloma
What this study did
NCT03180736 · Stichting European Myeloma Network
2017-06-14 – 2024-11-30 · Multiple Myeloma
What this study did
NCT05236621 · Qilu Pharmaceutical Co., Ltd.
2021-01-04 – 2023-12 · Multiple Myeloma, Recurrent or Refractory
What this study did
NCT03143049 · National University Hospital, Singapore
2017-09-13 – 2022-06-01 · Relapse Multiple Myeloma
What this study did
NCT01734928 · Celgene
2013-01-07 – 2022-05-13 · Multiple Myeloma
What this study did
NCT02726581 · Bristol-Myers Squibb
2016-08-10 – 2022-03-09 · Multiple Myeloma
What this study did
NCT03440411 · Fondazione EMN Italy Onlus
2016-02-18 – 2019-12-31 · Multiple Myeloma
What this study did
NCT02916420 · Jiangsu Simcere Pharmaceutical Co., Ltd.
2016-09 – 2019-06 · Multiple Myeloma
What this study did
Other / comorbidity
NCT01178281 · Celgene
2010-09-08 – 2018-05-15 · Primary Myelofibrosis, MPN-associated Myelofibrosis
What this study did
Phase 2/3 (1)
Multiple Myeloma
NCT06879379 · Peking University People's Hospital
2025-03 – 2029-03 · Multiple Myeloma, Newly Diagnosed
What this study did
Phase 2 (103)
Multiple Myeloma
NCT07748689 · Polish Myeloma Consortium
2026-10 – 2033-03 · Relapsed / Refractory Multiple Myeloma
What this study did
NCT07757412 · Odense University Hospital
2026-09-01 – 2032-01-01 · Multiple Myeloma Progression
What this study did
NCT04883242 · University of Washington
2021-07-29 – 2031-12-31 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT07825064 · Hoffmann-La Roche
2026-11-03 – 2031-01-19 · Multiple Myeloma
What this study did
NCT05922501 · Massachusetts General Hospital
2024-05-31 – 2030-12-31 · Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma
What this study did
NCT07096778 · CellCentric Ltd.
2026-01-22 – 2029-12-01 · Multiple Myeloma Refractory, Multiple Myeloma in Relapse
What this study did
NCT04850599 · OHSU Knight Cancer Institute
2022-06-14 – 2029-02-21 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT05669989 · Sanofi
2023-04-05 – 2028-11-30 · Plasma Cell Myeloma
What this study did
NCT05208307 · Emory University
2022-07-21 – 2028-10-21 · Plasma Cell Myeloma
What this study did
NCT05789303 · University of Chicago
2023-05-30 – 2028-07-01 · Multiple Myeloma, Relapse Multiple Myeloma
What this study did
NCT07018050 · Qilu Pharmaceutical Co., Ltd.
2025-09-12 – 2028-07 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT04176718 · Andrew Yee, MD
2020-05-18 – 2028-05 · Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
What this study did
NCT05911321 · UNC Lineberger Comprehensive Cancer Center
2023-12-05 – 2028-03-26 · Multiple Myeloma, Relapse, Refractory, Aging, Co-morbidity
What this study did
NCT04661137 · Hackensack Meridian Health
2021-03-16 – 2028-02 · Multiple Myeloma
What this study did
NCT04790474 · Tel-Aviv Sourasky Medical Center
2021-03-25 – 2028-01-01 · Multiple Myeloma in Relapse, Refractory Multiple Myeloma
What this study did
NCT04302324 · Weill Medical College of Cornell University
2021-10-28 – 2027-12-28 · Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
What this study did
NCT05050305 · Dana-Farber Cancer Institute
2024-03 – 2027-12 · Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
What this study did
NCT02718833 · Massachusetts General Hospital
2016-06-21 – 2027-12 · Multiple Myeloma
What this study did
NCT03030261 · Washington University School of Medicine
2017-11-22 – 2027-09-26 · Multiple Myeloma in Relapse
What this study did
NCT04124497 · Fondazione EMN Italy Onlus
2019-07-01 – 2027-07-01 · Multiple Myeloma, Deletion 17P Syndrome
What this study did
NCT04835129 · Medical College of Wisconsin
2022-01-10 – 2027-06-01 · Multiple Myeloma
What this study did
NCT04508790 · City of Hope Medical Center
2020-11-24 – 2027-02-14 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT04925193 · University of Colorado, Denver
2021-11-18 – 2026-11 · Multiple Myeloma in Relapse
What this study did
NCT03756896 · Emory University
2019-01-25 – 2026-06-30 · Plasma Cell Myeloma
What this study did
NCT04287855 · Poitiers University Hospital
2020-08-28 – 2026-04-15 · Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
What this study did
NCT02719613 · Bristol-Myers Squibb
2016-07-15 – 2026-02-23 · Multiple Myeloma
What this study did
NCT05298683 · Hellenic Society of Hematology
2022-05 – 2026-01 · Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases
What this study did
NCT04941937 · Juan Du
2022-01-27 – 2025-12-30 · Multiple Myeloma
What this study did
NCT05288062 · Mayo Clinic
2022-06-15 – 2025-07-30 · Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
What this study did
NCT05478993 · Peking University People's Hospital
2022-10-12 – 2025-07-10 · Multiple Myeloma
What this study did
NCT03590652 · University of California, San Diego
2018-10-17 – 2025-07-02 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT06255847 · Shanxi Bethune Hospital
2022-06-15 – 2025-06-15 · Multiple Myeloma in Relapse
What this study did
NCT02406222 · University of Leeds
2016-03 – 2025-06 · Multiple Myeloma
What this study did
NCT03227432 · Dana-Farber Cancer Institute
2018-12 – 2024-12-31 · Multiple Myeloma
What this study did
NCT04584307 · Natalie Callendar
2021-04 – 2024-12 · Multiple Myeloma
What this study did
NCT03713294 · Mayo Clinic
2019-01-14 – 2024-11-14 · Refractory Plasma Cell Myeloma
What this study did
NCT04191616 · Amgen
2020-08-06 – 2024-10-01 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT05432414 · RenJi Hospital
2022-12-08 – 2024-07-31 · Multiple Myeloma
What this study did
NCT04892446 · Gilead Sciences
2021-11-09 – 2024-04-25 · Multiple Myeloma
What this study did
NCT03731832 · GWT-TUD GmbH
2018-09-20 – 2024-04-22 · Refractory Multiple Myeloma
What this study did
NCT04700176 · Hackensack Meridian Health
2022-05-02 – 2023-11-15 · Multiple Myeloma
What this study did
NCT03683277 · Intergroupe Francophone du Myelome
2019-11-03 – 2023-02-10 · Multiple Myeloma, Relapsed and Refractory Multiple Myeloma, Genetic Condition
What this study did
NCT04843579 · Weill Medical College of Cornell University
2021-12-29 – 2022-12-30 · Myeloma Multiple, Myeloma, Refractory Multiple Myeloma
What this study did
NCT03959358 · University Health Network, Toronto
2020-07-03 – 2022-10-07 · Multiple Myeloma, Amyloidosis
What this study did
NCT03215524 · Canadian Myeloma Research Group
2017-10-25 – 2022-06-24 · Multiple Myeloma
What this study did
Phase 1/2 (52)
Multiple Myeloma
NCT07463807 · National Cancer Institute (NCI)
2027-04-12 – 2029-03-31 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT05714839 · GlaxoSmithKline
2023-06-14 – 2028-08-03 · Multiple Myeloma
What this study did
NCT06106945 · AstraZeneca
2023-12-05 – 2028-01-24 · Multiple Myeloma
What this study did
NCT03715478 · Canadian Myeloma Research Group
2018-11-26 – 2027-12-31 · Relapsed and/or Refractory Multiple Myeloma
What this study did
NCT04764942 · Mayo Clinic
2021-05-06 – 2027-12-17 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT02343042 · Karyopharm Therapeutics Inc
2015-10 – 2027-04 · Multiple Myeloma
What this study did
NCT04068597 · CellCentric Ltd.
2019-08-09 – 2027-03-31 · Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
What this study did
NCT04126200 · GlaxoSmithKline
2019-10-07 – 2027-03-11 · Multiple Myeloma
What this study did
NCT07150104 · GlaxoSmithKline
2022-08-31 – 2027-03-11 · Multiple Myeloma
What this study did
NCT04094961 · Omar Nadeem, MD
2019-09-18 – 2027-01-01 · Multiple Myeloma, Multiple Myeloma in Relapse
What this study did
NCT05581875 · Hellenic Society of Hematology
2022-10-20 – 2026-10-31 · Multiple Myeloma, Multiple Myeloma in Relapse, Neoplasms, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease, Neoplasms, Plasma Cell
What this study did
NCT05408026 · Alliance Foundation Trials, LLC.
2022-10-01 – 2026-02 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT01665794 · University of Chicago
2012-08-13 – 2025-11-14 · Multiple Myeloma
What this study did
NCT01754402 · Cristina Gasparetto
2013-01-07 – 2025-01-01 · Multiple Myeloma
What this study did
NCT03732703 · Multiple Myeloma Research Consortium
2019-04-01 – 2024-12-31 · Relapsed Refractory Multiple Myeloma
What this study did
NCT02542657 · Joseph Tuscano
2015-10-22 – 2024-11-11 · Myeloma
What this study did
NCT01592370 · Bristol-Myers Squibb
2012-08-02 – 2024-07-09 · Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma
What this study did
NCT01997840 · Celgene
2014-03-01 – 2024-02-29 · Multiple Myeloma
What this study did
NCT01166113 · Fondazione EMN Italy Onlus
2010-07 – 2023-06 · Multiple Myeloma
What this study did
NCT04762745 · Sun Yat-sen University
2021-02 – 2023-02 · Relapsed, Refractory, Multiple Myeloma
What this study did
NCT02185820 · European Myeloma Network B.V.
2014-06 – 2023-01 · Multiple Myeloma
What this study did
NCT02119468 · City of Hope Medical Center
2014-07-22 – 2022-12-01 · Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
What this study did
NCT02004275 · Alliance for Clinical Trials in Oncology
2014-02 – 2021-12-01 · Multiple Myeloma in Relapse
What this study did
NCT01421186 · MorphoSys AG
2011-07 – 2020-08 · Multiple Myeloma
What this study did
NCT01464034 · Criterium, Inc.
2011-11 – 2020-07 · Multiple Myeloma
What this study did
NCT02384083 · PETHEMA Foundation
2015-09 – 2020-03-23 · Multiple Myeloma
What this study did
NCT01946152 · M.D. Anderson Cancer Center
2014-03-05 – 2020-03-18 · Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT02548962 · Pharmacyclics LLC.
2016-03 – 2018-06-13 · Multiple Myeloma
What this study did
NCT01212952 · Mayo Clinic
2011-09 – 2018-03-22 · Refractory Multiple Myeloma
What this study did
NCT02206425 · Oncotherapeutics
2014-09 – 2018-03-06 · Multiple Myeloma
What this study did
NCT01522872 · Threshold Pharmaceuticals
2012-02 – 2017-09 · Multiple Myeloma
What this study did
NCT02289222 · Ashraf Badros
2014-12-30 – 2017-08-07 · Multiple Myeloma
What this study did
NCT01541332 · Oncotherapeutics
2012-02 – 2016-12 · Multiple Myeloma
What this study did
NCT01979276 · Weill Medical College of Cornell University
2013-11 – 2016-10 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07441954 · Institute of Hematology & Blood Diseases Hospital, China
2026-03-20 – 2029-12-31 · Indolent Lymphoma
What this study did
NCT06554561 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2024-08-31 – 2029-08-31 · PCNSL
What this study did
NCT06660498 · University of Aarhus
2025-05-13 – 2027-03-31 · HIV-1 Infection
What this study did
NCT06855823 · Sun Yat-sen University
2025-01-14 – 2026-12 · Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
What this study did
NCT01644110 · University of Ulm
2013-08 – 2024-04-27 · Primary Myelofibrosis, Secondary Myelofibrosis, PMF, SMF, Post-PV MF, Post-ET MF
What this study did
NCT05205252 · Epizyme, Inc.
2021-12-22 – 2023-07-05 · Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
What this study did
NCT01495598 · National Cancer Institute (NCI)
2012-01-10 – 2022-05-17 · Kaposi Sarcoma, Sarcoma, Kaposi
What this study did
NCT00669578 · Mayo Clinic
2008-05 – 2019-12-12 · Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
What this study did
NCT01570387 · Boston Medical Center
2012-06 – 2019-04 · AL Amyloidosis
What this study did
NCT02265510 · Incyte Corporation
2014-09-10 – 2019-02-27 · Solid Tumors, Advanced Malignancies, Metastatic Cancer
What this study did
NCT01432600 · H. Lee Moffitt Cancer Center and Research Institute
2011-11 – 2016-08 · Myeloma
What this study did
NCT02228512 · National Cancer Institute (NCI)
2014-08-15 – 2015-05-05 · Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease, Primary Effusion Lymphoma
What this study did
Phase 1 (67)
Multiple Myeloma
NCT07831122 · Canadian Myeloma Research Group
2026-12 – 2033-03 · Relapsed Refractory Multiple Myeloma (RRMM)
What this study did
NCT07720843 · Montefiore Medical Center
2026-09-01 – 2032-03 · Relapse Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT06768489 · Janssen Research & Development, LLC
2024-12-04 – 2029-06-29 · Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
What this study did
NCT04910568 · Genentech, Inc.
2021-07-26 – 2028-12-21 · Multiple Myeloma
What this study did
NCT05651932 · K36 Therapeutics, Inc.
2023-02-22 – 2028-06-30 · Multiple Myeloma, Myeloma, Myeloma Multiple
What this study did
NCT05050097 · Janssen Research & Development, LLC
2021-09-22 – 2027-12-31 · Multiple Myeloma
What this study did
NCT04108195 · Janssen Research & Development, LLC
2020-02-21 – 2027-12-31 · Multiple Myeloma
What this study did
NCT01562405 · Massachusetts General Hospital
2012-05 – 2027-12 · Multiple Myeloma
What this study did
NCT04722146 · Janssen Research & Development, LLC
2021-03-12 – 2027-10-13 · Multiple Myeloma
What this study did
NCT05556798 · Memorial Sloan Kettering Cancer Center
2022-10-04 – 2027-10 · Multiple Myeloma
What this study did
NCT04667663 · Cancer Trials Ireland
2021-12-08 – 2026-04-30 · Multiple Myeloma
What this study did
NCT03984097 · Takeda
2019-07-29 – 2026-03-25 · Multiple Myeloma
What this study did
NCT03657420 · Massachusetts General Hospital
2019-05-30 – 2024-09-30 · Multiple Myeloma
What this study did
NCT03828292 · GlaxoSmithKline
2019-03-14 – 2024-09-05 · Multiple Myeloma
What this study did
NCT04355039 · Medical College of Wisconsin
2021-07-01 – 2024-07-01 · Refractory Multiple Myeloma, Relapse Multiple Myeloma
What this study did
NCT05556616 · Teva Branded Pharmaceutical Products R&D LLC
2023-01-12 – 2024-06-04 · Multiple Myeloma
What this study did
NCT02400242 · Celgene
2015-05-07 – 2024-06-03 · Multiple Myeloma
What this study did
NCT04045795 · Sanofi
2019-08-06 – 2024-03-27 · Multiple Myeloma
What this study did
NCT03269136 · Pfizer
2017-11-29 – 2024-01-19 · Multiple Myeloma
What this study did
NCT01998971 · Janssen Research & Development, LLC
2014-02-18 – 2024-01-11 · Multiple Myeloma
What this study did
NCT04392648 · Teva Branded Pharmaceutical Products R&D LLC
2020-06-24 – 2023-11-10 · Relapsed and/or Refractory Multiple Myeloma
What this study did
NCT03582033 · Seagen Inc.
2018-11-01 – 2023-11-09 · Multiple Myeloma
What this study did
NCT03287908 · Amgen
2017-11-13 – 2023-06-30 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT02939183 · Amgen
2017-01-17 – 2022-10-06 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT03143985 · Koen van Besien
2017-07-21 – 2022-09-01 · Multiple Myeloma
What this study did
NCT03015922 · University of Leeds
2017-06-05 – 2021-10-01 · Multiple Myeloma
What this study did
NCT02283775 · Sanofi
2015-05-15 – 2021-05-26 · Plasma Cell Myeloma
What this study did
NCT02569320 · Ohio State University Comprehensive Cancer Center
2016-05-20 – 2021-03-10 · Recurrent Plasma Cell Myeloma
What this study did
NCT01999335 · Amgen
2014-07-30 – 2019-04-25 · Multiple Myeloma
What this study did
NCT01575925 · Celgene
2012-06-01 – 2018-08-07 · Multiple Myeloma, Renal Impairment
What this study did
NCT03023527 · PETHEMA Foundation
2017-01 – 2018-01 · Multiple Myeloma
What this study did
NCT02462525 · AbbVie
2015-05-06 – 2017-12-06 · Multiple Myeloma
What this study did
NCT02103335 · Celgene
2014-06-05 – 2016-11-30 · Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Multiple Myeloma
What this study did
NCT02071888 · Calithera Biosciences, Inc
2014-02 – 2016-04 · Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM), Other B-cell NHL Subtypes, Including WM, T-cell NHL
What this study did
NCT01889420 · New Mexico Cancer Research Alliance
2014-07 – 2015-07 · Multiple Myeloma in Relapse
What this study did
NCT01537861 · Washington University School of Medicine
2012-06 – 2014-12 · Multiple Myeloma
What this study did
Other / comorbidity
NCT05389423 · National Cancer Institute (NCI)
2023-06-27 – 2032-06-01 · Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, Plasmablastic Lymphoma, B-Cell Neoplasm
What this study did
NCT02659930 · National Cancer Institute (NCI)
2016-01-13 – 2029-01-01 · Kaposi Sarcoma
What this study did
NCT07532525 · University of Michigan Rogel Cancer Center
2026-08-26 – 2028-08 · Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma
What this study did
NCT04902443 · National Cancer Institute (NCI)
2021-12-10 – 2027-12-01 · Viral Associated Malignancies, Kaposi Sarcoma, EBV/KSHV-associated Lymphomas
What this study did
NCT01198067 · M.D. Anderson Cancer Center
2010-10-06 – 2025-05-02 · Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
What this study did
NCT06058689 · Megalabs
2024-09-15 – 2025-03-15 · Bioequivalence Study
What this study did
Phase 4 (4)
Multiple Myeloma
NCT04989140 · Peking Union Medical College Hospital
2021-07-26 – 2024-07-26 · Multiple Myeloma
What this study did
NCT05555329 · Amsterdam UMC, location VUmc
2022-12-01 – 2024-02-14 · Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory
What this study did
Other / comorbidity
NCT07760610 · The First Hospital of Jilin University
2026-09 – 2029-07 · Diffuse Large B-Cell Lymphoma (DLBCL)
What this study did
Early phase / not applicable (9)
Multiple Myeloma
NCT06924424 · Peking University People's Hospital
2025-03-01 – 2027-06-30 · Multiple Myeloma, Neoplasms
What this study did
NCT07015021 · The First Affiliated Hospital of Soochow University
2025-06-01 – 2026-09-30 · Multiple Myeloma, Carfilzomib, Daratumumab, Pomalidomide
What this study did
NCT05378971 · LanZhou University
2022-05-15 – 2025-05-30 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07257510 · Peking University Third Hospital
2025-08-01 – 2028-08-01 · Mantle Cell Lymphoma (MCL), POZ
What this study did
NCT07072208 · The First Affiliated Hospital of Soochow University
2024-11-01 – 2027-05-01 · Diffuse Large B-Cell Lymphoma
What this study did
NCT06376214 · Nanjing University School of Medicine
2023-01-01 – 2026-12-31 · Light Chain (AL) Amyloidosis
What this study did
NCT06832228 · Zhejiang Cancer Hospital
2024-09-01 – 2026-09-01 · Diffuse Large B-cell Lymphoma (DLBCL)
What this study did
NCT05809180 · The First Affiliated Hospital of Soochow University
2023-01-04 – 2026-07-03 · Diffuse Large B Cell Lymphoma
What this study did
Used as active comparator (28)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (22)
Multiple Myeloma
NCT05730036 · Regeneron Pharmaceuticals
2023-09-18 – 2033-04-19 · Relapsed Refractory Multiple Myeloma (RRMM)
What this study did
NCT06413498 · Kite, A Gilead Company
2024-08-23 – 2031-07 · Multiple Myeloma
What this study did
NCT07569757 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2026-06 – 2030-12 · Multiple Myeloma
What this study did
NCT06464991 · Nanjing IASO Biotechnology Co., Ltd.
2024-03-27 – 2030-12 · Multiple Myeloma
What this study did
NCT07910903 · Keymed Biosciences Co.Ltd
2026-12 – 2030-11 · Multiple Myeloma (MM)
What this study did
NCT07933432 · Qilu Pharmaceutical Co., Ltd.
2026-12-30 – 2030-05-21 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT07452198 · Genrix (Shanghai) Biopharmaceutical Co., Ltd.
2026-03-09 – 2030-03 · Multiple Myeloma
What this study did
NCT07623798 · Innovent Biologics (Suzhou) Co. Ltd.
2026-06-11 – 2029-12-31 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT07138209 · Qilu Pharmaceutical Co., Ltd.
2025-11-07 – 2029-12 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT07579234 · Shandong New Time Pharmaceutical Co., LTD
2026-01-25 – 2029-01-25 · Relapsed or Refractory Multiple Myeloma (RRMM)
What this study did
NCT04162210 · GlaxoSmithKline
2020-04-02 – 2027-03-11 · Multiple Myeloma
What this study did
NCT05675319 · Universitätsklinikum Hamburg-Eppendorf
2023-03-03 – 2025-03-21 · Multiple Myeloma
What this study did
NCT03151811 · Oncopeptides AB
2017-06-12 – 2023-02-03 · Multiple Myeloma
What this study did
Phase 2 (2)
Multiple Myeloma
NCT03170882 · Millennium Pharmaceuticals, Inc.
2017-08-01 – 2021-11-26 · Relapsed and/or Refractory Multiple Myeloma
What this study did
Phase 1/2 (4)
Multiple Myeloma
NCT04643002 · Sanofi
2021-01-25 – 2028-04-20 · Plasma Cell Myeloma Refractory
What this study did
NCT04150965 · Multiple Myeloma Research Consortium
2020-07-10 – 2024-08-30 · Multiple Myeloma, Relapsed Refractory Multiple Myeloma
What this study did
Other / comorbidity
NCT05451771 · Columbia University
2022-10-26 – 2027-09 · AL Amyloidosis
What this study did

Competitive landscape

Other Cereblon (CRBN) drugs

HRS-3738. Compare all 2 Cereblon (CRBN) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Multiple Myeloma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pomalidomide: this drugApprovedSmall moleculeCereblon (CRBN)Partial signal
NCT01324947: Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment (From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.): Pomalidomide 23%
NCT01311687: Progression-free Survival (PFS) - Primary Analysis (From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.): Pomalidomide Plus Low-Dose Dexamethasone 15.7 weeks (95% CI 13 to 20.1) vs High-Dose Dexamethasone 8 weeks (95% CI 7 to 9)
Belantamab MafodotinApprovedAntibody–drug conjugateBCMAPartial signal
NCT04246047: Progression-free Survival (PFS) (Up to approximately 41 months): Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) 36.6 Months vs Daratumumab + Bor + Dex 13.4 Months (95% CI 11.1 to 17.5)
NCT04162210: Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG) (Up to 27 months): Belantamab Mafodotin 11.2 Months (95% CI 6.4 to 14.5) vs Pomalidomide Plus Dexamethasone 7 Months (95% CI 4.6 to 10.6) missed
BortezomibApprovedSmall moleculeProteasomePartial signal
NCT00722566: Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73
NCT00048230: Response rate (CR+PR): 38% bortezomib vs 18% dexamethasone (P<0.001), with CR 6% vs <1%; median time to progression 6.22 vs 3.49 months (HR 0.55, P<0.001); 1-year survival 80% vs 66% (P=0.003), overall survival HR 0.57 (P=0.001).
CarfilzomibApprovedSmall moleculeProteasomePartial signal
NCT03158688: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants
NCT01568866: Progression-free Survival (From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively): Carfilzomib + DEX 18.7 months vs Bortezomib + DEX 9.4 months (95% CI 8.4 to 10.4)
Ciltacabtagene AutoleucelApprovedCell therapyBCMAPartial signal
NCT04181827: Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023).
DaratumumabApprovedMonoclonal antibodyCD38Partial signal
NCT03901963: Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months): Daratumumab + Lenalidomide 50.5% (95% CI 40.3 to 60.7) vs Lenalidomide 18.8% (95% CI 11.7 to 27.8)
NCT02076009: Progression-free survival at the interim analysis: hazard ratio 0.37 (95% CI 0.27 to 0.52; P<0.001); 12-month PFS 83.2% with daratumumab plus lenalidomide/dexamethasone vs 60.1% with lenalidomide/dexamethasone (POLLUX, N Engl J Med 2016).
ElotuzumabApprovedMonoclonal antibodySLAMF7 (CS1/CD319)Partial signal
NCT01335399: Progression-Free Survival (PFS) (From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)): E-Ld Cohort 31.38 Months (95% CI 26.18 to 36.8) vs Ld Cohort 29.47 Months (95% CI 23.49 to 34.3) missed
NCT01239797: Median Progression Free Survival (PFS) (From randomization up to 326 events (up to approximately 38 months)): Lenalidomide + Dexamethasone + Elotuzumab 19.35 Months (95% CI 16.62 to 22.18) vs Lenalidomide + Dexamethasone 14.85 Months (95% CI 12.09 to 17.22)
ElranatamabApprovedMultispecific antibodyBCMA x CD3Weak signalFeatured results are non-efficacy only in this race
Iberdomide (Zenbexus)ApprovedSmall moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Idecabtagene VicleucelApprovedCell therapyBCMAReliable signal
NCT03651128: PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001)
NCT03361748: Overall Response Rate (From first dose to 24 Months): BB2121 74.5% (95% CI 67.1 to 81.8)
IsatuximabApprovedMonoclonal antibodyCD38Partial signal
NCT02990338: Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): IPd (Isatuximab + Pomalidomide + Dexamethasone) 11.53 months (95% CI 8.936 to 13.897) vs Pd (Pomalidomide + Dexamethasone) 6.47 months (95% CI 4.468 to 8.279)
IxazomibApprovedSmall moleculeProteasomeReliable signal
NCT02312258: Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47)
NCT02181413: Progression Free Survival (PFS) (Randomization up to End of treatment (EOT) (24 months); thereafter followed up every 4 weeks (up to 45 months)): Ixazomib Citrate 26.5 months (95% CI 23.69 to 33.81) vs Placebo 21.3 months (95% CI 17.97 to 24.67)
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide AnalogReliable signal
NCT00424047: Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months): Lenalidomide Plus Dexamethasone 52.1 weeks vs Placebo Plus Dexamethasone 20.1 weeks (95% CI 16.6 to 20.7)
NCT00056160: Time to Tumor Progression (TTP) (60 weeks (median Time To Progression of CC-5013/Dex treatment group)): CC-5013/Dex 60.1 Weeks (95% CI 41.1 to 80) vs Placebo/Dex 20.1 Weeks (95% CI 16.1 to 21.1)
LinvoseltamabApprovedMultispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Melphalan Hydrochloride (Evomela)ApprovedSmall moleculeDNA (guanine N7 position)Weak signal
NCT03159702: Progression-free Survival (PFS) of Participants With Hematological Malignancies Undergoing Treatment. (1 year): MEL/FLU and Total-Body Irradiation (TBI) 17/43
MotixafortideApprovedPeptideCXCR4Partial signal
NCT03246529: Proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses (central laboratory), randomized Part 2, motixafortide + filgrastim (n=80) vs placebo + filgrastim (n=42): 67.5% vs 9.5%, adjusted difference 56.8%, p < 0.0001 (stratified Cochran-Mantel-Haenszel; APHEXDA US label, section 14). CT.gov posted results for the same randomized groups give 70.0% vs 14.3%, p < 0.0001 (Cochran-Mantel-Haenszel).
NCT02639559: Number of Donors That Mobilize ≥ 2 x 10^6 CD34+ Cells/kg of Recipients Weight After a Single Injection of BL-8040 After no More Than Two Leukapheresis Collections (Arm 1 - Donors Only) (Up to Day 2): Arm 1: Donors 22/24
PlerixaforApprovedSmall moleculeCXCR4Partial signal
NCT00103662: Collection of at least 6 x 10^6 CD34+ cells/kg in 2 or fewer aphereses: plerixafor plus G-CSF 71.6% (106/148) vs placebo plus G-CSF 34.4% (53/154), P<.001 (DiPersio et al., Blood 2009).
SelinexorApprovedSmall moleculeXPO1 (exportin-1)Partial signal
NCT03110562: SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) (From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)): SVd Arm: Selinexor + Bortezomib + Dexamethasone 13.93 Months vs Vd Arm: Bortezomib + Dexamethasone 9.46 Months (95% CI 8.11 to 10.78)
TalquetamabApprovedMultispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
TeclistamabApprovedMultispecific antibodyBCMA x CD3Partial signal
NCT05083169: Primary endpoint, progression-free survival: teclistamab plus daratumumab was statistically significant and superior to DPd/DVd (J&J, 2025-10-16).
NCT04696809: Phase 2 primary endpoint ORR 76.9% (>=VGPR 76.9%, >=CR 65.4%) in 26 patients at RP2D 1.5 mg/kg; median follow-up 14.32 months
ThalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligasePartial signalFeatured results are non-efficacy only in this race
Zoledronic Acid (Zometa)ApprovedSmall moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
PanobinostatUS approval withdrawnSmall moleculeHDACPartial signal
NCT01023308: Progression-free survival (investigator-assessed): median 11.99 months with panobinostat + bortezomib + dexamethasone vs 8.08 months with placebo + bortezomib + dexamethasone; HR 0.63 (95% CI 0.52-0.76), p<0.0001 (Lancet Oncology 2014)
Anitocabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
Arlocabtagene AutoleucelPhase 3Cell therapyGPRC5DWeak signalFeatured results are safety only in this race
AZD0120Phase 3Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
BCD-264Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
CevostamabPhase 3Multispecific antibodyFcRH5 (FcRL5) x CD3not yet gradedNo reviewed efficacy summary in this indication
CT-P44Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLReliable signal
NCT01345019: Time to First On-study Skeletal Related Event (From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.): Denosumab 695 days vs Zoledronic Acid 730 days (95% CI 504 to 1014)
Equecabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
EtentamigPhase 3Multispecific antibodyBCMA x CD3Partial signal
NCT06158841: Dual primary endpoints met: objective response rate and progression-free survival vs standard available therapies (PFS HR 0.40, P<0.0001) (AbbVie, 2026-09-03).
F182112Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
FelzartamabPhase 3Monoclonal antibodyCD38Partial signal
NCT03952091: Median PFS: 18·9 months felzartamab+Rd vs 10·4 months Rd (hazard ratio 0·62; p=0·0035)
Gamgertamig (CM336)Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
HLX15Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
IBI3003Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
InobrodibPhase 3Small moleculeCBP/p300 (bromodomain)not yet gradedNo reviewed efficacy summary in this indication
LumrotatugPhase 3Monoclonal antibodyCD38Weak signal
NCT04818372: CM313 phase 1 dose-escalation/expansion (NCT04818372, anti-CD38 mAb, R/R multiple myeloma + marginal zone lymphoma): grade>=3 TEAEs 15/34 (44.1%), no DLTs; ORR 34.5% among 29 evaluable RRMM patients; median PFS 132 days.
MezigdomidePhase 3Small moleculeCereblon E3 ubiquitin-ligasePartial signal
NCT05552976: Primary endpoint, progression-free survival: statistically significant and clinically meaningful improvement vs carfilzomib and dexamethasone (Bristol Myers Squibb, 2026-03-09).
PlitidepsinPhase 3Small moleculeeEF1A2 (eukaryotic translation elongation factor 1-alpha 2)Partial signal
NCT01102426: Progression Free Survival (PFS) as Per Intention-to-treat (ITT) (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years): Plitidepsin+Dexamethasone 2.6 months (95% CI 1.9 to 3) vs Dexamethasone 1.7 months (95% CI 1.1 to 2)
QL2109Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
QLS32015Phase 3Multispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
QLS4131Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
RamantamigPhase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
SanritatugPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 3Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
TorutamigPhase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
TQB2934Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Velinotamig (GR1803)Phase 3Multispecific antibodyBCMA x CD3Weak signalNo reviewed efficacy summary in this indication
VenetoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Burixafor (TG-0054)Phase 2Small moleculeCXCR4Weak signal
NCT01458288: Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): TG-0054 (3.14 mg/kg) 7/7 | TG-0054 (3.14 mg/kg)+G-CSF 5/5
NCT01018979: Primary mobilization success: 2/4 patients in the TG-0054 2.24 mg/kg group (MM 1, NHL 1) vs 1/3 patients in the 3.14 mg/kg group (MM 1); no p-value or confidence interval reported.
CemsidomidePhase 2Small moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Hrain Anti-BCMA CAR-TPhase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
HRC0202Phase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
Iopofosine I-131Phase 2Radiopharmaceuticalphospholipid ether (selective lipid raftWeak signal
NCT02278315: The phase 1 dose-escalation and safety study enrolled 31 patients with relapsed or refractory multiple myeloma who had received a median of four prior lines of therapy. It established 31.25 mCi/m2 as the maximum tolerated single dose and identified 20 mCi/m2 administered twice, one week apart, as the highest evaluated fractionated dose regimen.
LMY-920Phase 2Cell therapyBCMA / TACInot yet gradedNo reviewed efficacy summary in this indication
RAPA-201Phase 2Cell therapyRapamycin-resistant autologous T-cell therapyWeak signal
NCT04176380: Overall response rate: 9/14 patients (64%) achieved disease remission (IMWG criteria) - 8 partial responses, 1 stringent complete response.
YKST02Phase 2Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD4045Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BCMA CAR-NK (Shenzhen Pregene Biopharma)Phase 1/2Cell therapyBCMAWeak signalNo reviewed efficacy summary in this indication
HRS-3738Phase 1Small moleculeCereblon (CRBN)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 61 furthest-along competitors are listed; 106 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(65 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Pomalidomide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (8)
November 2026 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT04973605 · CT.gov ↗
What to watch
December 2026 (7)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2026-12 · NCT01562405 · CT.gov ↗
What to watch
Phase 1/2Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)Recruiting
Est. primary completion 2026-12 · NCT06855823 · CT.gov ↗
What to watch
Phase 2Systemic AmyloidosisRecruiting
Est. primary completion 2026-12 · NCT06342466 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2026-12 · NCT02718833 · CT.gov ↗
What to watch
Phase 1Viral Associated Malignancies, Kaposi Sarcoma, EBV/KSHV-associated LymphomasRecruiting
Est. primary completion 2026-12-01 · NCT04902443 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2026-12-31 · NCT04883242 · CT.gov ↗
What to watch
Early phase / not applicableMultiple MyelomaActive not recruiting
Est. primary completion 2026-12-31 · NCT06924424 · CT.gov ↗
What to watch
2027 (25)
January 2027 (1)
Phase 2Amyloid, AL Amyloidosis, Refractory AL AmyloidosisActive not recruiting
Est. primary completion 2027-01 · NCT04270175 · CT.gov ↗
What to watch
February 2027 (2)
Phase 2Skin Kaposi SarcomaActive not recruiting
Est. primary completion 2027-02-04 · NCT04577755 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-14 · NCT04508790 · CT.gov ↗
What to watch
March 2027 (3)
Phase 1/2HIV-1 InfectionActive not recruiting
Est. primary completion 2027-03-31 · NCT06660498 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-03-31 · NCT04068597 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-03-31 · NCT06508983 · CT.gov ↗
What to watch
April 2027 (3)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-04-01 · NCT04835129 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2027-04-07 · NCT04108195 · CT.gov ↗
What to watch
May 2027 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-05 · NCT04176718 · CT.gov ↗
What to watch
Early phase / not applicableDiffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-05-01 · NCT07072208 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2027-06-01 · NCT03715478 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-07-01 · NCT04124497 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-07-30 · NCT05455320 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia …Recruiting
Est. primary completion 2027-08 · NCT07532525 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-09-01 · NCT04790474 · CT.gov ↗
What to watch
October 2027 (3)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2027-10 · NCT05556798 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-10-15 · NCT04850599 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-10-21 · NCT05208307 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-11 · NCT07018050 · CT.gov ↗
What to watch
December 2027 (5)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2027-12 · NCT06742138 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-12 · NCT06158841 · CT.gov ↗
What to watch
Phase 1/2Indolent LymphomaNot yet recruiting
Est. primary completion 2027-12-05 · NCT07441954 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12-30 · NCT06615479 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT05651932 · CT.gov ↗
What to watch
2028 (16)
January 2028 (2)
Phase 1Kaposi SarcomaActive not recruiting
Est. primary completion 2028-01-01 · NCT02659930 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2028-01-24 · NCT06106945 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-02 · NCT04661137 · CT.gov ↗
What to watch
March 2028 (3)
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2028-03 · NCT06879379 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-25 · NCT05137054 · CT.gov ↗
What to watch
Phase 2Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL)Recruiting
Est. primary completion 2028-03-31 · NCT07523737 · CT.gov ↗
What to watch
June 2028 (2)
Phase 2Malignant Plasma Cell NeoplasmsNot yet recruiting
Est. primary completion 2028-06 · NCT07560449 · CT.gov ↗
What to watch
Phase 1Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, Plasmablastic Lymphoma, B-Cell NeoplasmRecruiting
Est. primary completion 2028-06-01 · NCT05389423 · CT.gov ↗
What to watch
July 2028 (2)
Phase 4Diffuse Large B-Cell Lymphoma (DLBCL)Not yet recruiting
Est. primary completion 2028-07 · NCT07760610 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-07-01 · NCT05789303 · CT.gov ↗
What to watch
August 2028 (2)
Early phase / not applicableMantle Cell Lymphoma (MCL), POZRecruiting
Est. primary completion 2028-08-01 · NCT07257510 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2028-08-03 · NCT05714839 · CT.gov ↗
What to watch
November 2028 (2)
Phase 2Multiple MyelomaEnrolling by invitation
Est. primary completion 2028-11-30 · NCT05669989 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2028-11-30 · NCT07555938 · CT.gov ↗
What to watch
December 2028 (2)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-12-21 · NCT04910568 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-12-31 · NCT05922501 · CT.gov ↗
What to watch
2029 (9)
January 2029 (3)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2029-01-01 · NCT07757412 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2029-01-02 · NCT06768489 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-01-31 · NCT05438043 · CT.gov ↗
What to watch
March 2029 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2029-03-31 · NCT07463807 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-04-13 · NCT07825064 · CT.gov ↗
What to watch
May 2029 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-05-21 · NCT07222761 · CT.gov ↗
What to watch
November 2029 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-11 · NCT07772024 · CT.gov ↗
What to watch
December 2029 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-12-01 · NCT07096778 · CT.gov ↗
What to watch
Phase 2DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma)Recruiting
Est. primary completion 2029-12-31 · NCT07749365 · CT.gov ↗
What to watch
2030 (2)
March 2030 (1)
Phase 1Multiple MyelomaNot yet recruiting
Est. primary completion 2030-03 · NCT07720843 · CT.gov ↗
What to watch
August 2030 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2030-08-30 · NCT07227311 · CT.gov ↗
What to watch
2033 (4)
January 2033 (1)
Phase 1Multiple MyelomaNot yet recruiting
Est. primary completion 2033-01 · NCT07831122 · CT.gov ↗
What to watch
February 2033 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2033-02 · NCT07728188 · CT.gov ↗
What to watch
March 2033 (1)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2033-03 · NCT07748689 · CT.gov ↗
What to watch
September 2033 (1)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2033-09 · NCT05259839 · CT.gov ↗
What to watch
2035 (1)
December 2035 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2035-12 · NCT06892522 · CT.gov ↗
What to watch

See the full readout calendar ↗